
|Articles|July 1, 2004
FDA allows four firms to make generic solution
Washington, DC-Four manufacturers of ocular products have received FDA approval to market ofloxacin ophthalmic solution 0.3%, a generic version of Allergan Inc.'s Ocuflox, for the treatment of certain strains of bacteria in conjunctivitis and corneal ulcers.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Moorfields study reveals sharp rise in glaucoma burden across the UK
2
Nanoscope’s gene therapy, MCO-010 receives Sakigake and Orphan Drug Designations in Japan
3
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
4
Why individualized glaucoma care remains essential amid uneven patient awareness
5














































